002349 精华制药
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)4.8798.2198.45910.2249.154
总资产报酬率 ROA (%)3.7886.3826.5567.9566.802
投入资产回报率 ROIC (%)4.8248.1188.3039.9098.479

边际利润分析
销售毛利率 (%)54.26151.88949.67748.69346.733
营业利润率 (%)25.40820.84221.04421.88515.987
息税前利润/营业总收入 (%)24.88819.19317.72920.27814.950
净利润/营业总收入 (%)21.89417.93417.65018.28813.495

收益指标分析
经营活动净收益/利润总额(%)99.43198.36499.52799.04795.843
价值变动净收益/利润总额(%)2.0172.5512.7922.14511.772
营业外收支净额/利润总额(%)0.526-0.224-0.593-0.352-0.508

偿债能力分析
流动比率 (X)5.4305.1355.6655.4934.381
速动比率 (X)4.6754.4324.8344.6883.602
资产负债率 (%)10.67911.79510.43911.95413.749
带息债务/全部投入资本 (%)0.3630.1210.6771.5362.917
股东权益/带息债务 (%)27,179.41081,875.94914,562.8516,358.8253,295.692
股东权益/负债合计 (%)731.981653.654749.587642.053574.080
利息保障倍数 (X)-38.036-11.979-5.555-13.244-15.630

营运能力分析
应收账款周转天数 (天)80.99475.54769.28655.71649.519
存货周转天数 (天)143.629140.347143.192138.913135.503